Ovarian cancer is the eighth most common form of cancer in
the United States, according to the Centers for Disease Control and Prevention,
and it’s the fifth leading cause of cancer deaths. This dangerous form of
cancer begins as a growth of abnormal malignant cells in the ovaries before
spreading to other sites within the body. Although we still don’t know exactly
what causes ovarian cancers, we do know that some factors make women more
likely to develop epithelial ovarian cancer during their lifetime. According to
the American Cancer Society, both inherited genetic mutations and acquired
genetic changes can place women at a heightened risk of developing this
dangerous condition.
For women in an elevated risk category for ovarian cancer,
regular screening and, if necessary, early detection can play a major role in
overall health and wellbeing. If diagnosed in its early stages, ovarian cancer
is an extremely survivability illness. When discovered in stage one,
approximately 92 percent of ovarian cancer cases surpass the recorded five-year
survival milestone. Despite this statistic, the average five-year survival rate
for ovarian cancer is just 44 percent. This is because only 15 percent of
ovarian cancers are currently diagnosed during stage one, according to
Healthline.
Avant Diagnostics, Inc. (OTCQB: AVDX) is on a mission to
improve the survivability of ovarian cancer by giving women access to more
effective early detection technology. The company’s pre-symptomatic ovarian
cancer screening test, OvaDx®, is a leading breakthrough in the field of
ovarian cancer diagnostics. OvaDx is a sophisticated microarray-based test that
measures the activation of the immune system in blood samples in response to
early stage ovarian tumor cell development. In clinical research, the test has
indicated high sensitivity and specificity for all types and stages of ovarian
cancer.
Following FDA approval, Avant intends to offer OvaDx as an
elective test for women in the elevated risk category for ovarian cancer, as
well as those seeking greater wellness. As the market’s first large panel
screening test for ovarian cancer, OvaDx is expected to greatly improve the
early diagnosis rate of ovarian cancer and, as a result, advance the
survivability of this deadly disease.
For more information, visit www.avantdiagnostics.com
About QualityStocks
QualityStocks
is committed to connecting subscribers with companies that have huge potential
to succeed in the short and long-term future. We offer several ways for
investors to find, evaluate, and learn more about investing in these companies.
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
No comments:
Post a Comment